Takeda shareholders back dividend and board slate

Takeda Pharmaceutical Company Limited reports the voting results from its 150th Annual General Meeting of Shareholders held on June 24, 2026.

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited reports the voting results from its 150th Annual General Meeting of Shareholders held on June 24, 2026. Shareholders approved a year-end dividend of 100 JPY per common share and elected all nominated directors, including eight non–Audit and Supervisory Committee members and three committee members.

They also approved one substitute director and authorized up to 260 million JPY in bonuses for eligible directors. All proposals passed with large majorities, with most director elections receiving approval rates above 90% of voting rights exercised.

Key Figures

Year-end dividend: 100 JPY per share Director bonuses cap: 260 million JPY AGM date: June 24, 2026 +5 more

8 metrics

Year-end dividend 100 JPY per share Proposal No.1, year-end dividend on common stock

Director bonuses cap 260 million JPY Proposal No.5, bonuses for 2 eligible directors

AGM date June 24, 2026 150th Annual General Meeting of Shareholders

Dividend approval ratio 98.45% Proposal No.1, proportion of approval

Proposal 5 approval ratio 82.94% Bonuses to directors, proportion of approval

Votes for dividend 11,994,528 voting rights Approval votes on Proposal No.1

Votes for Julie Kim 11,840,220 voting rights Election as director, Proposal No.2

Votes for Paul Stoffels (substitute) 11,999,993 voting rights Election as Substitute Director, Proposal No.4

Key Terms

Appropriation of Surplus, Audit and Supervisory Committee Members, Substitute Director, Financial Instruments and Exchange Act, +1 more

5 terms

Appropriation of Surplus financial

"Proposal No.1: Appropriation of Surplus Concerning the year-end dividend 100 JPY per share"

Audit and Supervisory Committee Members financial

"Election of Eight (8) Directors who are not Audit and Supervisory Committee Members"

Substitute Director financial

"Election of One (1) Substitute Director who is an Audit and Supervisory Committee Member"

Financial Instruments and Exchange Act regulatory

"submitted pursuant to the provisions of Article 24-5, Paragraph 4 in the Financial Instruments and Exchange Act"

voting rights financial

"Numbers of voting rights for approval of, against and abstaining from each of the items"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What dividend did Takeda (TAK) shareholders approve at the 150th AGM?

Takeda shareholders approved a year-end dividend of 100 JPY per share for common stock. This dividend was confirmed at the 150th Annual General Meeting held on June 24, 2026, through a resolution with strong majority support.

Which director elections were approved at Takeda (TAK)’s 150th shareholder meeting?

Shareholders approved eight directors who are not Audit and Supervisory Committee Members and three who are committee members. All nominated individuals, including Julie Kim, Paul Stoffels, and Bruce Broussard, received majority support above 90% of voting rights exercised.

Were director bonuses approved at Takeda (TAK)’s June 2026 AGM?

Yes, shareholders approved up to 260 million JPY in bonuses for two directors who are not Audit and Supervisory Committee Members, excluding directors residing outside Japan and external directors. The bonus proposal passed with an approval ratio of 82.94% of voting rights exercised.

How strong was support for Takeda (TAK)’s dividend proposal at the AGM?

The dividend proposal received 11,994,528 voting rights in favor versus 2,199 against, with 25 abstentions. This corresponded to an approval proportion of 98.45% of voting rights exercised, easily meeting the majority requirement for passage.

When was Takeda (TAK)’s 150th Annual General Meeting of Shareholders held?

Takeda’s 150th Annual General Meeting of Shareholders was held on June 24, 2026. The meeting covered dividend decisions, director elections, a substitute director appointment, and authorization of director bonuses, with all resolutions approved by the required shareholder majorities.

Why were some shareholder votes at Takeda (TAK)’s AGM not counted in the final tallies?

The company states that required approval thresholds were already met through advance voting and confirmed votes from some attendees. Because the legal requirements were satisfied, remaining votes from other attendees were not added to the approval, opposition, or abstention counts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 06:32 AM EDT Learn about SEC filing dates

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of June 2026

Commission File Number: 001-38757

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome

Chuo-ku, Tokyo 103-8668

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Information furnished on this form:

EXHIBIT

Exhibit Number
99.1						Results of the Exercise of Voting Rights of the 150th Annual General Meeting of Shareholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

						TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: June 26, 2026						By:			/s/ Norimasa Takeda
									Norimasa Takeda Chief Accounting Officer and Corporate Controller

Results of the Exercise of Voting Rights of the 150th Annual General Meeting of Shareholders 1. Reason for the submission The report is submitted pursuant to the provisions of Article 24-5, Paragraph 4 in the Financial Instruments and Exchange Act, and Article 19, Paragraph 2, Item 9-2 in the Cabinet Office Ordinance on Disclosure of Corporate Information, etc., which shows the results of the resolution on the items to be resolved at the 150th Annual General Meeting of Shareholders of the Company held on June 24, 2026. 2. Contents [1] The date of the shareholders meeting June 24, 2026 [2] Details of items to be resolved Proposal No.1: Appropriation of Surplus Concerning the year-end dividend 100 JPY per share of common stock of the Company Proposal No.2: Election of Eight (8) Directors who are not Audit and Supervisory Committee Members To elect Julie Kim, Milano Furuta, Andrew Plump, Masami Iijima, Steven Gillis, John Maraganore, Miki Tsusaka and Paul Stoffels as Directors who are not Audit and Supervisory Committee Members. Proposal No.3: Election of Three (3) Directors who are Audit and Supervisory Committee Members To elect Kimberly A. Reed, Bruce Broussard and Koichiro Kimura as Directors who are Audit and Supervisory Committee Members. Proposal No.4: Election of One (1) Substitute Director who is an Audit and Supervisory Committee Member To elect Paul Stoffels as a Substitute Director who is an Audit and Supervisory Committee Member. Proposal No.5: Payment of Bonuses to Directors who are not Audit and Supervisory Committee Members To pay bonuses within a total of 260 million JPY to the 2 Directors who are not Audit and Supervisory Committee Members (excluding Directors residing outside of Japan and External Directors) in office as of the end of this fiscal year.

[3] Numbers of voting rights for approval of, against and abstaining from each of the items to be resolved, requirements for each of the items to be resolved to be approved and the results for each resolution Item to be resolved Approval (No. of voting rights) Against (No. of voting rights) Abstention (No. of voting rights) Total No. of voting rights exercised Result (Proportion of approval) Approval requirements Proposal No.1 11,994,528 2,199 25 12,183,048 Approval (98.45%) (Note) 1 Proposal No.2 (Note) 2 Julie Kim 11,840,220 223,449 9,105 12,183,109 Approval (97.19%) Milano Furuta 11,392,485 679,968 25 12,182,813 Approval (93.51%) Andrew Plump 11,274,783 797,914 25 12,183,057 Approval (92.54%) Masami Iijima 11,584,361 488,316 25 12,183,037 Approval (95.09%) Steven Gillis 11,619,791 452,859 25 12,183,010 Approval (95.38%) John Maraganore 11,571,136 501,534 25 12,183,030 Approval (94.98%) Miki Tsusaka 11,603,016 469,663 25 12,183,039 Approval (95.24%) Paul Stoffels 11,962,283 110,380 25 12,183,023 Approval (98.19%) Proposal No.3 (Note) 2 Kimberly A. Reed 11,659,554 412,957 25 12,183,027 Approval (95.70%) Bruce Broussard 11,184,764 887,743 25 12,183,023 Approval (91.81%) Koichiro Kimura 11,963,428 109,105 25 12,183,049 Approval (98.20%) Proposal No.4 (Note) 2 Paul Stoffels 11,999,993 72,670 25 12,183,025 Approval (98.50%) Proposal No.5 10,104,535 1,946,260 21,968 12,183,074 Approval (82.94%) (Note) 1 (Note) 1. Approval requires a majority of the voting rights of shareholders in attendance and able to exercise voting rights. 2. Approval requires the attendance of shareholders possessing at least one third of the voting rights of shareholders who are able to exercise voting rights and a majority of the voting rights of shareholders in attendance.

[4] Reason for not adding some of the voting rights of shareholders who attended the Annual General Meeting of Shareholders to the number of voting rights for approval of, against or abstaining from each of the items to be resolved The requirements for approval of the resolutions were met by the advance voting by the day prior to the date of this Annual General Meeting of Shareholders and the tallying of votes received from some of the shareholders who attended on the day of the meeting for which the approval or otherwise of the resolutions could be confirmed, and the resolutions were thus passed legally in accordance with the Companies Act. Therefore, the remaining votes of shareholders who attended on the day of this Annual General Meeting of Shareholders were not added to the number of voting rights for approval of, against or abstaining from each of the items to be resolved. End of Document

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 5.7 KB